Megan F. Whelan

Use of human immunoglobulin in addition to glucocorticoids for the initial treatment of dogs with immune-mediated hemolytic anemia

OBJECTIVE To determine the utility of human intravenous immunoglobulin (hIVIG) for the initial treatment of canine immune-mediated hemolytic anemia (IMHA). DESIGN Blinded, randomized, clinical trial. SETTING Veterinary teaching hospital. ANIMALS Twenty-eight, client-owned dogs with primary IMHA. INTERVENTIONS At enrollment, after diagnosis of IMHA, dogs were randomly assigned to receive either hIVIG or placebo, in a blinded fashion. For the next 14 days, all dogs received glucocorticoids as the sole immunosuppressant agent. All dogs received low-molecular-weight heparin as an anticoagulant. D-dimer concentrations were evaluated at the beginning and end of the study protocol to monitor for thromboembolic complications. MEASUREMENTS AND MAIN RESULTS Twenty-five of 28 dogs (89%) were discharged from the hospital. Thirteen of those received hIVIG and 12 received placebo. Twenty-four dogs (86%) were alive 14 days after enrollment, and of these 13 received hIVIG and 11 received placebo. D-dimer concentrations were elevated in 86% of all dogs at the time of diagnosis. CONCLUSIONS For initial treatment of dogs with IMHA, the addition of hIVIG to corticosteroid treatment did not improve initial response, nor did it shorten hospitalization.

Use of mycophenolate mofetil as a rescue agent in the treatment of severe generalized myasthenia gravis in three dogs

OBJECTIVE To describe the use of IV and oral mycophenolate mofetil (MMF) as adjunctive therapy in 3 dogs with severe generalized myasthenia gravis. CASE SERIES SUMMARY Three dogs suffering from severe generalized myasthenia gravis as confirmed by acetylcholine antibody titers were treated with MMF as part of their treatment regimens. All 3 dogs had radiographic evidence of megaesophagus and suffered from severe regurgitation. Each dog was initially treated with pyridostigmine and supportive agents. When clinical remission was not achieved, IV MMF was administered to all dogs. Signs of clinical remission were apparent within 48 hours and all dogs were later maintained on oral MMF following resolution of regurgitation. NEW OR UNIQUE INFORMATION PROVIDED This is the first report of the use of IV MMF as adjunctive treatment in dogs with severe generalized myasthenia gravis. Outcome was favorable in all 3 dogs and no adverse effects were noted from the MMF.

Myasthenia gravis in dogs with an emphasis on treatment and critical care management

Objective – To review the human and veterinary literature on the pathophysiology of myasthenia gravis (MG) and describe treatment options for clinical use in people and animals. Data Sources – Human and veterinary clinical reports, studies and reviews, textbooks, and recent research findings in MG from 1996 present, with a focus on treatment and patient management. Human Data Synthesis – MG is a well-described condition in people with new research and treatment options available. Many of the newest therapeutic options available in veterinary medicine for MG are based on current strategies used in people with this condition. Seronegative MG is well described in people and provides insight to clinical cases encountered in veterinary medicine when the index of suspicion is high though serologic tests are negative. Veterinary Data Synthesis – Previous studies in veterinary medicine focused on the use of acetylcholinesterase inhibitors as the main form of treatment in canine MG. Recent studies, mainly case series and case reports, emphasize the use of immunomodulatory treatments as an alternative for long-term treatment. However, there are no randomized, controlled studies on treatment with immunomodulatory therapy for MG in dogs available to assess the efficacy of this treatment strategy. Conclusions – Although early recognition of clinical signs is most important in the outcome of patients with MG, further understanding the pathophysiology of MG may lead to earlier diagnosis and novel treatment strategies. The discovery of additional autoantibodies against striated muscle proteins in dogs, should enhance our understanding of diseases affecting the neuromuscular junction. In addition, clinical data for canine MG could be applied to other autoimmune disorders.OBJECTIVE To review the human and veterinary literature on the pathophysiology of myasthenia gravis (MG) and describe treatment options for clinical use in people and animals. DATA SOURCES Human and veterinary clinical reports, studies and reviews, textbooks, and recent research findings in MG from 1996 present, with a focus on treatment and patient management. HUMAN DATA SYNTHESIS MG is a well-described condition in people with new research and treatment options available. Many of the newest therapeutic options available in veterinary medicine for MG are based on current strategies used in people with this condition. Seronegative MG is well described in people and provides insight to clinical cases encountered in veterinary medicine when the index of suspicion is high though serologic tests are negative. VETERINARY DATA SYNTHESIS Previous studies in veterinary medicine focused on the use of acetylcholinesterase inhibitors as the main form of treatment in canine MG. Recent studies, mainly case series and case reports, emphasize the use of immunomodulatory treatments as an alternative for long-term treatment. However, there are no randomized, controlled studies on treatment with immunomodulatory therapy for MG in dogs available to assess the efficacy of this treatment strategy. CONCLUSIONS Although early recognition of clinical signs is most important in the outcome of patients with MG, further understanding the pathophysiology of MG may lead to earlier diagnosis and novel treatment strategies. The discovery of additional autoantibodies against striated muscle proteins in dogs, should enhance our understanding of diseases affecting the neuromuscular junction. In addition, clinical data for canine MG could be applied to other autoimmune disorders.

Fournier's gangrene in a cat

OBJECTIVE To describe the clinical course of a cat diagnosed with Fourniers gangrene. CASE SUMMARY A 2-year-old castrated male cat was presented to an emergency hospital for evaluation of acute onset of lethargy, mucoid anal discharge, and fever. During hospitalization, with provision of supportive care, an area of necrotizing fasciitis around the prepuce and anus developed and surgical debridement was performed. Severe sepsis developed secondary to the necrotizing fasciitis and the cat was eventually euthanized. NEW INFORMATION PROVIDED The purpose of this report is to document the first case of Fourniers gangrene in a cat that presented for mucoid anal discharge, lethargy, and mild ataxia, and to alert emergency clinicians to this disease process. Early detection of the disease with prompt, aggressive supportive care and surgical debridement is necessary for successful treatment.

Compartment syndrome: pathophysiology, clinical presentations, treatment, and prevention in human and veterinary medicine

OBJECTIVE To review the human and veterinary literature pertaining to all forms of compartment syndrome (CS). DATA SOURCES Data sources included scientific reviews and original research publications from the human and veterinary literature. HUMAN DATA SYNTHESIS While CS affecting the extremities has been recognized in people for decades, other forms of CS in the abdominal and thoracic cavities are recently gaining more attention. The role of CS in critically ill people is a rapidly growing area of interest. More research on prevention and treatment of CS is being conducted in people because some studies have found mortality rates as high as 80% for those suffering from these conditions. VETERINARY DATA SYNTHESIS While a significant amount of experimental studies of CS have been performed on small animals, there is a marked lack of primary veterinary studies. The majority of the veterinary literature includes case reports and series, and many of these studies were published over a decade ago. However, the increased recognition of CS in people has sparked an interest in veterinary critical care medicine and this has been demonstrated by the recent increased evaluation of compartment pressures in veterinary patients. CONCLUSIONS CS is a complex clinical condition where increased pressure within a compartment can cause significant adverse effects within the compartment as well as throughout the body. Systemic inflammatory responses and local ischemia-reperfusion elements can contribute to the detrimental effects seen in CS. This cascade of events results in increased mortality rates and contributes to the development of CS elsewhere. A better understanding of CS will help veterinarians improve patient care and outcome. Future studies on incidence, prevention, and treatment of CSs in the critical care patient are needed in veterinary medicine.Objective To review the human and veterinary literature pertaining to all forms of compartment syndrome (CS). Data Sources Data sources included scientific reviews and original research publications from the human and veterinary literature. Human Data Synthesis While CS affecting the extremities has been recognized in people for decades, other forms of CS in the abdominal and thoracic cavities are recently gaining more attention. The role of CS in critically ill people is a rapidly growing area of interest. More research on prevention and treatment of CS is being conducted in people because some studies have found mortality rates as high as 80% for those suffering from these conditions. Veterinary Data Synthesis While a significant amount of experimental studies of CS have been performed on small animals, there is a marked lack of primary veterinary studies. The majority of the veterinary literature includes case reports and series, and many of these studies were published over a decade ago. However, the increased recognition of CS in people has sparked an interest in veterinary critical care medicine and this has been demonstrated by the recent increased evaluation of compartment pressures in veterinary patients. Conclusions CS is a complex clinical condition where increased pressure within a compartment can cause significant adverse effects within the compartment as well as throughout the body. Systemic inflammatory responses and local ischemia-reperfusion elements can contribute to the detrimental effects seen in CS. This cascade of events results in increased mortality rates and contributes to the development of CS elsewhere. A better understanding of CS will help veterinarians improve patient care and outcome. Future studies on incidence, prevention, and treatment of CSs in the critical care patient are needed in veterinary medicine.

Baclofen toxicosis in dogs and cats: 145 cases (2004-2010).

OBJECTIVE To identify dogs and cats with baclofen toxicosis and characterize the patient population, clinical signs, and outcome. DESIGN Retrospective case series. ANIMALS 140 dogs and 5 cats with baclofen toxicosis. PROCEDURES An animal poison control center electronic database was reviewed from November 2004 through April 2010 to identify dogs and cats with baclofen toxicosis. Information on signalment, clinical signs, and amount of baclofen ingested was obtained. Clinical signs were categorized as CNS, gastrointestinal, general malaise, cardiovascular, respiratory, or urogenital. Follow-up communications were performed to determine overall outcome. RESULTS Dogs had a median age of 0.67 years (range, 0.1 to 15 years) and cats of 1 year (range, 0.7 to 16 years). Of 145 patients, 133 (92%) developed clinical signs of baclofen toxicosis. A total of 259 signs fell within defined categories: CNS (121/259 [46.7%]), gastrointestinal (69/259 [26.6%]), general malaise (27/259 [10.4%]), cardiovascular (23/259 [8.9%]), respiratory (14/259 [5.4%]), and urogenital (5/259 [1.9%]). For 68 dogs with known survival status, survival rate was 83.8% (57/68); of these dogs, the amount of baclofen ingested was known for 53 (46 survivors and 7 nonsurvivors). Amount of baclofen ingested was significantly lower in survivor dogs (median, 4.2 mg/kg [1.91 mg/lb]; range, 0.61 to 61 mg/kg [0.28 to 27.7 mg/lb]), compared with nonsurvivor dogs (median, 14 mg/kg [6.4 mg/lb]; range, 2.3 to 52.3 mg/kg [1.04 to 23.77 mg/lb]. Of 5 cats, 2 survived, 1 died, and 2 had unknown outcomes. CONCLUSIONS AND CLINICAL RELEVANCE Clinical signs of baclofen toxicosis occurred in most patients, with the CNS being the system most commonly affected.

Sleep aid toxicosis in dogs: 317 cases (2004-2010).

OBJECTIVE To summarize the signalment, clinical signs observed, time to onset of clinical signs, duration of clinical signs, and the outcome in a large case series of nonbenzodiazepine sleep aid ingestions in dogs, including 2 sleep aids that have not been previously described in the veterinary literature. DESIGN Retrospective study conducted between 2004 and 2010. SETTING An animal poison control center based out of Bloomington, MN. ANIMALS During this time frame, 453 cases were identified involving 467 dogs. Of these cases, 150 cases were excluded due to incomplete medical records, multipet households, or the inability to calculate a dose exposure. A total of 317 dogs with presumed sleep aid medication toxicosis were included. INTERVENTIONS None. MEASUREMENTS AND MAIN RESULTS Records of dogs with sleep aid medication toxicosis identified by a review of an animal poison control center electronic database were evaluated. The most common sleep aid medications ingested were zolpidem (240/317 [75.7%]), eszopiclone (62/317 [19.5%]), and zaleplon (15/317 [4.7%]). Overall, clinical signs developed in 36% of patients (115/317), while 64% (202/317) remained asymptomatic. The most common organ systems affected and clinical signs seen involved the central nervous system (eg, agitation, sedation) and gastrointestinal tract (eg, anorexia, hypersalivation, vomiting). CONCLUSIONS Overall, the prognosis for dogs with sleep aid medication toxicosis was excellent, and no fatalities were reported in this clinical population. As significant clinical signs can still be seen with ingestion, appropriate decontamination is warranted in asymptomatic patients via emesis or gastric lavage, followed by activated charcoal administration. Symptomatic patients should be hospitalized for monitoring and supportive care for a minimum of 12 hours or until clinical signs resolve.

Nonsurgical pneumoperitoneum in a dog secondary to blunt force trauma to the chest.

OBJECTIVE To describe the medical management of pneumoperitoneum without surgical intervention in a dog that sustained blunt force trauma to the thorax. To review the mechanisms of how a thoracic injury (ie, extra-abdominal source) can lead to pneumoperitoneum. CASE SUMMARY A 4-month-old Shih Tzu puppy was attacked by a larger dog and sustained various injuries including a pneumothorax, pneumomediastinum, and a pneumoperitoneum. The dog presented minimally responsive and in respiratory distress secondary to pulmonary contusions and noncardiogenic pulmonary edema. No penetrating wounds to the abdomen or thorax were identified. As no immediate surgical lesion was identified the dog was treated conservatively without the need for surgical intervention. The dog was successfully managed and discharged after a few days of supportive care with oxygen therapy. Before discharge, repeat radiographs revealed complete resolution of the pneumothorax, pneumomediastinum, and pneumoperitoneum. NEW OR UNIQUE INFORMATION PROVIDED Cases of nonsurgical pneumoperitoneum have rarely been reported in the veterinary literature. A thoracic source of pneumoperitoneum should be considered when the suspicion of a ruptured viscus is low based on diagnostic procedures (eg, ultrasound, computed tomography, and diagnostic peritoneal lavage), in addition to physical examination (eg, lack of fever and absence of abdominal pain) and laboratory findings (eg, absence of inflammatory leukogram).Objective To describe the medical management of pneumoperitoneum without surgical intervention in a dog that sustained blunt force trauma to the thorax. To review the mechanisms of how a thoracic injury (ie, extra-abdominal source) can lead to pneumoperitoneum. Case Summary A 4-month-old Shih Tzu puppy was attacked by a larger dog and sustained various injuries including a pneumothorax, pneumomediastinum, and a pneumoperitoneum. The dog presented minimally responsive and in respiratory distress secondary to pulmonary contusions and noncardiogenic pulmonary edema. No penetrating wounds to the abdomen or thorax were identified. As no immediate surgical lesion was identified the dog was treated conservatively without the need for surgical intervention. The dog was successfully managed and discharged after a few days of supportive care with oxygen therapy. Before discharge, repeat radiographs revealed complete resolution of the pneumothorax, pneumomediastinum, and pneumoperitoneum. New or unique information provided Cases of nonsurgical pneumoperitoneum have rarely been reported in the veterinary literature. A thoracic source of pneumoperitoneum should be considered when the suspicion of a ruptured viscus is low based on diagnostic procedures (eg, ultrasound, computed tomography, and diagnostic peritoneal lavage), in addition to physical examination (eg, lack of fever and absence of abdominal pain) and laboratory findings (eg, absence of inflammatory leukogram).

Factor VIII inhibitors complicating treatment of postoperative bleeding in a dog with hemophilia A

OBJECTIVE To describe the clinical course of a dog with hemophilia A and circulating factor VIII inhibitors complicating the treatment of postoperative hemorrhage. CASE SUMMARY A 7-year-old castrated male Japanese Chin with hemophilia A, weighing 6 kg, was presented for dental cleaning, polishing, and extractions. Despite presurgical administration of cryoprecipitate, continuous oral bleeding occurred. Circulating factor VIII inhibitors were detected, and the postoperative hemorrhage was subsequently managed with extensive and prolonged blood component transfusion. The dog was discharged after a full clinical recovery. NEW OR UNIQUE INFORMATION PROVIDED This case report describes the clinical consequences and successful treatment of postoperative hemorrhage in a dog with hemophilia A and circulating factor VIII inhibitors. A relevant discussion of the management of human patients with circulating factor VIII inhibitors is included.

Escalator-related injuries in 30 dogs (2007-2014): Escalator injuries in 30 dogs

Objective To describe a population of dogs affected by escalator-related injuries, and to characterize the types of injuries sustained and describe treatment administered. Design Retrospective study from March 2007 to November 2014. Setting Large urban referral and emergency facility. Animals Thirty client-owned dogs presenting with injuries acquired while riding an escalator. Interventions None. Measurements and Main Results All injuries in this study occurred secondary to entrapment of 1 or more paws in the moving parts of an escalator; 39 paws were injured in total. The median body weight of the patients in this study was 4.25 kg, with 73.3% of the patients weighing less than 10 kg. Fifteen patients (50.0%) were treated surgically, the remainder were managed conservatively. Eight patients (26.7%) underwent digit or partial-digit amputation. Of the conservatively managed patients, 10 were treated with bandaging of the wounds. Antimicrobials, opiate analgesics, and nonsteroidal anti-inflammatory drugs were administered in both surgically and conservatively managed patients. Conclusions While uncommon, escalator accidents can result in significant injury to dogs. Measures can be taken to prevent these injuries from occurring, whether through client education, dog training, structural modifications in the escalators themselves, or avoidance of escalators. In the present study, the survival rate of dogs injured on escalators was 100%.OBJECTIVE To describe a population of dogs affected by escalator-related injuries, and to characterize the types of injuries sustained and describe treatment administered. DESIGN Retrospective study from March 2007 to November 2014. SETTING Large urban referral and emergency facility. ANIMALS Thirty client-owned dogs presenting with injuries acquired while riding an escalator. INTERVENTIONS None. MEASUREMENTS AND MAIN RESULTS All injuries in this study occurred secondary to entrapment of 1 or more paws in the moving parts of an escalator; 39 paws were injured in total. The median body weight of the patients in this study was 4.25 kg, with 73.3% of the patients weighing less than 10 kg. Fifteen patients (50.0%) were treated surgically, the remainder were managed conservatively. Eight patients (26.7%) underwent digit or partial-digit amputation. Of the conservatively managed patients, 10 were treated with bandaging of the wounds. Antimicrobials, opiate analgesics, and nonsteroidal anti-inflammatory drugs were administered in both surgically and conservatively managed patients. CONCLUSIONS While uncommon, escalator accidents can result in significant injury to dogs. Measures can be taken to prevent these injuries from occurring, whether through client education, dog training, structural modifications in the escalators themselves, or avoidance of escalators. In the present study, the survival rate of dogs injured on escalators was 100%.